EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease

Information

  • Research Project
  • 10383586
  • ApplicationId
    10383586
  • Core Project Number
    R41AG076098
  • Full Project Number
    1R41AG076098-01
  • Serial Number
    076098
  • FOA Number
    PA-20-265
  • Sub Project Id
  • Project Start Date
    9/30/2021 - 2 years ago
  • Project End Date
    3/29/2022 - 2 years ago
  • Program Officer Name
    LUO, YUAN
  • Budget Start Date
    9/30/2021 - 2 years ago
  • Budget End Date
    3/29/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/21/2021 - 2 years ago

EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease

PROJECT SUMMARY / ABSTRACT Alzheimer's disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extracellular vesicles (EVs) are important biomarkers for AD. However, researchers face significant challenges in the efficient isolation and accurate analysis of EVs, limiting the broad study and application of EVs in early diagnosis or targeted therapy of AD. WellSIM proposes to develop and validate a high-throughput platform and workflow based on our revolutionary EXODUS technique for reliable and reproducible isolation and analysis of EVs from plasma and CSF with unparalleled throughput, purity, yield, and sensitivity. Based on hi-EXODUS-NGS and hi-EXODUS-MS integrative analysis, transcriptomic and proteomic profiling of EVs will be developed to discover and detect EV-derived multi-class biomarkers for AD diagnosis.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R41
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    251359
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:251359\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
    081096834
  • Organization City
    Berkeley
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94710
  • Organization District
    UNITED STATES